C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent * Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma * Have progression by least one systemic treatment and no available standard of care treatment. * At least one measurable lesion by Lugano 2014 * Expected survival ≥ 12 weeks * Have an ECOG performance status of 0 or 1 * Adequate organ function * Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy * Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial Exclusion Criteria: * Treatment with any prior HSCT, gene therapy product, cell therapy product ect. * Central nervous system involvement * HBV/HCV * HIV infection * Concurrent use of systemic steroids or immunosuppression * Uncontrolled active infection * Wash-out period of from the last anti-cancer treatment * Active second malignancy * Have not recovered from the effects of previous therapy * Have psychological or physical conditions that do not permit compliance with the protocol * Pregnant or nursing (lactating) women